Product logins

Find logins to all Clarivate products below.


Trauma Devices | Market Insights | Asia Pacific (Supplemental) | 2024

In recent years, the Asia Pacific trauma device market has been negatively impacted by various events, including the COVID-19 pandemic, which diminished procedure volumes at the time, as well as the introduction of the volume-based procurement policy by the Chinese government, which is placing downward pressure on ASPs in the country. Nonetheless, favorable demographics and rising adoption of innovative devices will continue to support overall market growth through 2032.

This Medtech 360 Report provides high-level market metrics for trauma devices in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the Asia Pacific region from 2019 through 2032.

Related Medtech Insights Reports

Report
Structural Heart Closure Devices – Market Insights – Asia Pacific
The Asia Pacific structural heart closure device market will grow strongly overall through 2034, supported by rising AF prevalence, increasing physician confidence in structural heart interventions…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…
Report
Trauma Devices – Market Insights – Latin America
The Latin American trauma device market is positioned for strong growth, driven by the rapid expansion of highvolume product segments, a growing aging population, and increasingly favorable…
Report
Trauma Devices – Market Insights – Europe
Although financial constraints among European healthcare facilities and the rise of GPOs that will exert downward pressure on ASPs will limit the European trauma device market, favorable…
Report
Diabetes Care Devices – Market Insights – Asia Pacific
The Asia Pacific diabetes care device market is expected to experience moderate growth over the forecast period, driven by a rising diabetes population, untapped market opportunities, regulatory…